New data for Arexvy, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease: London, UK Friday, October 25, 2024, 13:00 Hr ...
GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...
This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
GSK (GSK) reported its RSV vaccine Arexvy elicited a robust immune response in people aged 18 to 49 years who were at ...
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
Hosted on MSN22h
GSK’s Arexvy Vaccine Shows Promise for Broader UseGlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback